Condition
Relapsed Solid Neoplasm
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Withdrawn1
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04773782Phase 1Completed
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
NCT05060276Phase 1WithdrawnPrimary
Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors
NCT04900519Phase 1Unknown
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
Showing all 3 trials